Adaptimmune Reports Results of Lete-cel in P-II Trial to Treat Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
Shots:
- The P-II (IGNYTE-ESO) evaluates the safety, efficacy & tolerability of lete-cel (1-15 × 10^9) in two sub-studies (SS) involving patients (n=45) with previously untreated synovial sarcoma or MRCLS (SS1) & in those who received anthracycline CT (SS2)
- As per the independent & investigator review, data depicted a RECISTv1.1 response in 40% & 33% of the patients & a response rate of 39% & 30% (synovial sarcoma) & 41% & 36% (MRCLS). Moreover, CR & partial response were depicted in 4.4% & 35% of patients (Independent review)
- DoR is being followed in 50% of respondents at the time of data cut-off, with a range of.18+ - 16.6+mos. Also, of the 5 evaluable patients in SS1, ORR was 80%, & 20% & 60% of patients had CR & partial response
Ref: Adaptimmune | Image: Adaptimmune
Related News:- Adaptimmune Reports P-II (SPEARHEAD-1) Trial Results of Afami-cel for the Treatment of Synovial Sarcoma at CTOS 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
